Development of PNAG-based vaccines
Vaccines using PNAG antigens with specific glucosamine monomer units and acetylation patterns, conjugated to bacteriophage QP capsids, address the challenge of inducing strong anti-carbohydrate responses, effectively combating antimicrobial-resistant pathogens like S. aureus.
Patent Information
- Application Number
- AU2024402378
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-21
- Filing Date
- 2024-12-19
- Publication Date
- 2026-07-23
AI Technical Summary
There is a need for effective vaccines against antimicrobial-resistant pathogens like Staphylococcus aureus, as current strategies face challenges in inducing strong anti-carbohydrate antibody responses without triggering high anti-carrier antibody responses, and existing vaccines are ineffective against strains such as methicillin-resistant S. aureus (MRSA).
Development of vaccine compositions comprising poly-0-(1->6)-N-acetylglucosamine (PNAG) antigens, specifically designed with varying glucosamine monomer units and acetylation patterns, conjugated to carrier systems like bacteriophage QP capsids to enhance immune response and reduce anti-carrier antibody interference.
The PNAG-based vaccines elicit high levels of anti-PNAG IgG antibodies, providing effective protection against S. aureus infections, including MRSA, with prolonged antibody responses and improved opsonic killing activities.
Smart Images
Figure 00000000_0000_ABST